Improving the sexual and reproductive health of people living with HIV

SFU health sciences professor Angela Kaida wants to help shape health policies and programs to support HIV-affected women to safely achieve their reproductive desires and enjoy healthy and satisfying sex lives.

And now that her Canada Research Chair in Global Perspectives on HIV and Sexual and Reproductive Health has been renewed, she has the funding she needs to continue her ground-breaking research on sexual and reproductive well-being among HIV-affected individuals.

As a Tier 2 Canada Research Chair, the global health epidemiologist will build on her previous work focused on the sexual and reproductive health and rights of women and men living with HIV. In rural Uganda, she is investigating the effect of a safer, patient-centered contraception intervention to support HIV-affected individuals and couples who desire children, while eliminating HIV transmission risk to the uninfected partner.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below